Phenibut tablets 250mg №10×2

Name Phenibut tab. 250mg in a box 10×2 The main active ingredient Gamma-amino-beta-phenylbutyric acid hydrochloride Release form Tablets Dosage 250 mg Pharmacological action Phenibut has a positive effect on metabolic processes in the nerve cells of the brain. The active substance of phenibut (?-amino-?-phenylbutyric acid hydrochloride) can be considered as a derivative of ?-amino-butyric acid (GABA) or as a derivative of ?-phenylethylamine. Phenibut has nootropic activity, and as a GABA derivative it has an anxiolytic (tranquilizing) effect. Does not affect cholinergic and adrenergic receptors. The drug reduces tension, anxiety, fear and improves sleep, so it is used to treat neuroses and before operations. Phenibut lengthens and enhances the action of hypnotics, narcotic, antipsychotic and antiparkinsonian drugs. Phenibut is devoid of anticonvulsant activity. Phenibut lengthens the latent period of nystagmus and shortens its duration and severity. The drug significantly reduces the manifestations of asthenia and vasovegetative symptoms, including headache, a feeling of heaviness in the head, sleep disturbances, irritability, emotional lability and increases mental performance. Psychological indicators (attention, memory, speed and accuracy of sensory-motor reactions) improve under the influence of phenibut, in contrast to the influence of tranquilizers. In patients with asthenia and in emotionally labile patients, from the first days of therapy, subjective well-being improves, interest and initiative increase, activity motivation increases without unnecessary sedation or arousal. Indications for use Asthenic and anxiety-neurotic conditions: anxiety, fear, anxiety. In elderly patients – sleep disturbances, restless night sleep. Prevention of anxiety conditions that occur before surgical interventions and painful diagnostic studies. Meniere’s disease: dizziness associated with dysfunction of the vestibular analyzer of various origins; prevention of motion sickness in kinetosis (a condition characterized by nausea, vomiting, dizziness, vestibular disorders and is caused by being in a moving object). In children – treatment of stuttering, tics. As an auxiliary drug in the complex treatment of alcohol withdrawal syndrome. Dosage and administration Inside, after eating. Adults are prescribed 250-500 mg 3 times a day. The maximum single dose in adult patients is 750 mg, in patients over 60 years of age – 500 mg. The course of treatment is 2-3 weeks. If necessary, the course can be extended up to 4-6 weeks. The duration of the course of treatment is determined by the doctor, taking into account the characteristics of the disease, the tolerability of the drug and the effect achieved. Children aged 8 to 14 years – 250 mg 3 times a day. Children over 14 years of age are prescribed doses for adults. For the relief of alcohol withdrawal syndrome in the first days of treatment – 250-500 mg 3 times during the day and 750 mg at night, with a gradual decrease in the daily dose to the usual for adults. With Meniere’s disease and syndrome during an exacerbation – 750 mg 3 times a day for 5-7 days, with a decrease in the severity of vestibular disorders – 250-500 mg 3 times a day for 5-7 days and then – 250 mg 1 time per day for 5 days. For mild diseases – 250 mg 2 times a day for 5-7 days, followed by a dose reduction to 250 mg 1 time per day for 7-10 days. For the treatment of dizziness with dysfunctions of the vestibular analyzer of vascular and traumatic origin – 250 mg 3 times a day for 12 days. For the prevention of motion sickness – 250-500 mg once 1 hour before the intended trip (the effect is dose-dependent). Phenibut is ineffective in the development of pronounced symptoms of motion sickness (“indomitable” vomiting, dizziness and other symptoms). In patients with impaired liver function, high doses of phenibut may cause a hepatotoxic effect. Patients in this group are prescribed smaller doses of the drug under the control of liver function. There are no data on the adverse effects of phenibut on patients with impaired renal function when taking therapeutic doses. Use during pregnancy and lactation Adequate and well-controlled studies to assess the safety of the use of the drug in women during pregnancy and lactation have not been conducted. Phenibut should not be used during pregnancy and lactation. Impact on the ability to drive vehicles and other potentially dangerous mechanisms It is necessary to refrain from potentially hazardous activities that require increased attention. Precautions With prolonged use, it is necessary to monitor liver function and peripheral blood picture. Caution should be exercised in patients with erosive and ulcerative diseases of the gastrointestinal tract due to the irritant effect of the drug. These patients are prescribed smaller doses of the drug. The preparation contains lactose. Should not be used in patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Use in children The drug in this form of release can be administered to children from 8 years of age. Interaction with other drugs Extends and enhances the effect of hypnotics, narcotic analgesics, antiepileptic, antipsychotic and antiparkinsonian drugs. Should not be combined with alcohol intake. Contraindications Classification of undesirable adverse reactions according to the frequency of development: very often (? 1/10); often (? 1/100 to < 1/10); infrequently (? 1/1000 to < 1/100); rarely (? 1/10,000 to <1/1000); very rarely (< 1/10,000); * - the frequency of manifestation is unknown (it is impossible to determine from the available data). Nervous system disorders *: drowsiness (at the beginning of treatment), increased irritability, agitation, anxiety, dizziness, headache. Gastrointestinal disorders*: nausea (at the beginning of treatment). Skin and subcutaneous tissue disorders: rarely - allergic reactions (skin rash, itching). Liver and biliary tract disorders *: with prolonged use of high doses - hepatotoxicity. In the event of the above adverse reactions or adverse reactions not listed in these instructions for medical use of the drug, you should consult a doctor. Composition Each tablet contains: active ingredient: phenibut - 250 mg; excipients: lactose monohydrate, povidone K-25, calcium stearate, potato starch. Overdose There are no reports of cases of overdose. In case of an overdose, the following symptoms are possible: drowsiness, nausea, vomiting, dizziness. With prolonged use of very high doses, eosinophilia, arterial hypotension, fatty degeneration of the liver, and impaired renal function may develop. In case of overdose, treatment is symptomatic. There is no specific antidote. Side effect Classification of undesirable side reactions according to the frequency of development: very often (? 1/10); often (? 1/100 to < 1/10); infrequently (? 1/1000 to < 1/100); rarely (? 1/10,000 to <1/1000); very rarely (< 1/10,000); * - the frequency of manifestation is unknown (it is impossible to determine from the available data). Nervous system disorders *: drowsiness (at the beginning of treatment), increased irritability, agitation, anxiety, dizziness, headache. Gastrointestinal disorders*: nausea (at the beginning of treatment). Skin and subcutaneous tissue disorders: rarely - allergic reactions (skin rash, itching). Liver and biliary tract disorders *: with prolonged use of high doses - hepatotoxicity. In the event of the above adverse reactions or adverse reactions not listed in these instructions for medical use of the drug, you should consult a doctor. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Buy Phenibut tablets 250mg No. 10x2 Price for Phenibut tablets 250mg No. 10x2